Gossamer Bio Securities Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 56 minutes ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Class Action Deadline: Purchasers of Gossamer Bio, Inc. (NASDAQ: GOSS) securities are reminded that the lead plaintiff deadline for the class action is June 1, 2026, and missing this date will prevent participation in potential compensation, impacting investor rights.
- No Out-of-Pocket Fees: Investors can seek compensation through the class action without any upfront costs, which reduces financial risk for investors and encourages more affected parties to join the lawsuit.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and enhancing investor confidence in their representation.
- Case Details Disclosure: The lawsuit alleges that defendants made false and misleading statements regarding Gossamer's PROSERA study, leading to investor losses when the true information was revealed, underscoring the importance of transparency and accurate disclosures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.341
Low
10.00
Averages
12.33
High
15.00
Current: 0.341
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Securities Class Action Notice
- Class Action Deadline: Purchasers of Gossamer Bio, Inc. (NASDAQ: GOSS) securities are reminded that the lead plaintiff deadline for the class action is June 1, 2026, and missing this date will prevent participation in potential compensation, impacting investor rights.
- No Out-of-Pocket Fees: Investors can seek compensation through the class action without any upfront costs, which reduces financial risk for investors and encourages more affected parties to join the lawsuit.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and enhancing investor confidence in their representation.
- Case Details Disclosure: The lawsuit alleges that defendants made false and misleading statements regarding Gossamer's PROSERA study, leading to investor losses when the true information was revealed, underscoring the importance of transparency and accurate disclosures.
See More
Multiple Companies Face Class Action Lawsuits
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose critical patient data from Latin American sites, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with investors able to file as lead plaintiffs by June 1, 2026.
- New Era Energy Allegations: New Era Energy & Digital (NASDAQ:NUAI) is accused of overstating progress in regulatory filings for its Texas Critical Data Centers project and engaging in fraudulent schemes, with a lead plaintiff deadline of June 1, 2026.
- Medpace Holdings Claims: Medpace Holdings (NASDAQ:MEDP) is facing a class action for misrepresenting its projected book-to-bill ratio for Q4 2025, with investors allowed to file as lead plaintiffs by June 5, 2026, highlighting a lack of reasonable basis for the company's optimistic statements.
- Legal Consultation Reminder: Affected investors are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights, indicating that these class actions could negatively impact the companies' stock prices.
See More
Reminder of Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors participating in the lawsuit will not incur any out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Case Background: The lawsuit alleges that Gossamer Bio made false and misleading statements regarding its Phase 3 PROSERA study, resulting in investor losses when the true information was revealed, highlighting the company's lack of transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors having until June 1, 2026, to apply as Lead Plaintiff.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its PROSERA study for seralutinib failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance, which did not meet the required 0.025 alpha threshold.
- Stock Price Plunge: Following the disappointing clinical trial results, Gossamer's stock price fell by $1.71, or 80.13%, closing at $0.42 per share on February 23, 2026, indicating a significant loss of investor confidence.
- Legal Firm Reputation: Pomerantz LLP is recognized as a leading firm in class action litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise in handling complex legal cases.
See More
Multiple Companies Face Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is accused of failing to disclose risks of declining advertising revenues during the class period from February 2025 to February 2026, potentially leading to restructuring and negatively impacting future financial performance.
- New Era Energy Violations: New Era Energy & Digital, Inc. faces allegations of overstating progress on its Texas data center project and engaging in fraudulent schemes to evade liabilities, which could result in materially misleading financial results and erode investor confidence.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. failed to meet the primary endpoint in its clinical trial from 2025 to 2026, as patients performed well on placebo, leading to accusations that prior positive statements were misleading, potentially harming its market reputation.
- Medpace Holdings Performance Inflation: Medpace Holdings, Inc. is accused of making false statements regarding its projected book-to-bill ratio for Q4 2025, failing to adequately assess the impact of cancellations, which may lead to diminished investor confidence in the company's future performance.
See More
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, alleging that misleading information led to inflated stock prices.
- False Statements Revealed: The lawsuit claims that Gossamer provided overly positive statements regarding its Phase 3 PROSERA study for treating pulmonary arterial hypertension while concealing significant adverse facts about the study design, particularly regarding placebo response control at Latin American sites, misleading investors.
- Investor Rights Protection: Affected investors must apply by June 1, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to help investors understand their rights and potential claims.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm representing individual and institutional investors in securities, derivative, and commercial litigation, with extensive litigation experience and a nationwide practice.
See More
Gossamer Bio Securities Class Action Notice
- Class Action Deadline: Purchasers of Gossamer Bio, Inc. (NASDAQ: GOSS) securities are reminded that the lead plaintiff deadline for the class action is June 1, 2026, and missing this date will prevent participation in potential compensation, impacting investor rights.
- No Out-of-Pocket Fees: Investors can seek compensation through the class action without any upfront costs, which reduces financial risk for investors and encourages more affected parties to join the lawsuit.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and enhancing investor confidence in their representation.
- Case Details Disclosure: The lawsuit alleges that defendants made false and misleading statements regarding Gossamer's PROSERA study, leading to investor losses when the true information was revealed, underscoring the importance of transparency and accurate disclosures.
See More
Multiple Companies Face Class Action Lawsuits
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose critical patient data from Latin American sites, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with investors able to file as lead plaintiffs by June 1, 2026.
- New Era Energy Allegations: New Era Energy & Digital (NASDAQ:NUAI) is accused of overstating progress in regulatory filings for its Texas Critical Data Centers project and engaging in fraudulent schemes, with a lead plaintiff deadline of June 1, 2026.
- Medpace Holdings Claims: Medpace Holdings (NASDAQ:MEDP) is facing a class action for misrepresenting its projected book-to-bill ratio for Q4 2025, with investors allowed to file as lead plaintiffs by June 5, 2026, highlighting a lack of reasonable basis for the company's optimistic statements.
- Legal Consultation Reminder: Affected investors are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights, indicating that these class actions could negatively impact the companies' stock prices.
See More
Reminder of Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors participating in the lawsuit will not incur any out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Case Background: The lawsuit alleges that Gossamer Bio made false and misleading statements regarding its Phase 3 PROSERA study, resulting in investor losses when the true information was revealed, highlighting the company's lack of transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors having until June 1, 2026, to apply as Lead Plaintiff.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its PROSERA study for seralutinib failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance, which did not meet the required 0.025 alpha threshold.
- Stock Price Plunge: Following the disappointing clinical trial results, Gossamer's stock price fell by $1.71, or 80.13%, closing at $0.42 per share on February 23, 2026, indicating a significant loss of investor confidence.
- Legal Firm Reputation: Pomerantz LLP is recognized as a leading firm in class action litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise in handling complex legal cases.
See More
Multiple Companies Face Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is accused of failing to disclose risks of declining advertising revenues during the class period from February 2025 to February 2026, potentially leading to restructuring and negatively impacting future financial performance.
- New Era Energy Violations: New Era Energy & Digital, Inc. faces allegations of overstating progress on its Texas data center project and engaging in fraudulent schemes to evade liabilities, which could result in materially misleading financial results and erode investor confidence.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. failed to meet the primary endpoint in its clinical trial from 2025 to 2026, as patients performed well on placebo, leading to accusations that prior positive statements were misleading, potentially harming its market reputation.
- Medpace Holdings Performance Inflation: Medpace Holdings, Inc. is accused of making false statements regarding its projected book-to-bill ratio for Q4 2025, failing to adequately assess the impact of cancellations, which may lead to diminished investor confidence in the company's future performance.
See More
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, alleging that misleading information led to inflated stock prices.
- False Statements Revealed: The lawsuit claims that Gossamer provided overly positive statements regarding its Phase 3 PROSERA study for treating pulmonary arterial hypertension while concealing significant adverse facts about the study design, particularly regarding placebo response control at Latin American sites, misleading investors.
- Investor Rights Protection: Affected investors must apply by June 1, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to help investors understand their rights and potential claims.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm representing individual and institutional investors in securities, derivative, and commercial litigation, with extensive litigation experience and a nationwide practice.
See More
